The Child-Pugh classification commonly is used for classifying patients with hepatocellular carcinoma and considering their eligibility for a clinical trial, but results of a retrospective study suggest that the albumin-bilirubin grade might be more useful.
“Our data suggests that the ALBI grade may improve the prognostic power for risk stratification,” reported investigator Munaf Alkadimi, MD, an oncologist and a hospitalist at the University of Texas Health Science Center.
In